Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

• Conditions: Gastrointestinal Stromal Tumor

• Registration Number: NCT01613053
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.

Detailed Description

Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial, all five patients will receive Glivec (8oomg per day) treatment until tumor progression \[by RECIST guidelines, version 1.0\], unacceptable toxicity, death or withdrawal of consent.

Study Timeline

• Study First Submitted: 2012-06-04
• Study First Submitted QC: 2012-06-04
• Study First Posted: 2012-06-06
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-23
• Last Update Posted: 2015-04-24

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained.

Exclusion Criteria

• N/A.

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (1)

Novartis Investigative Site; 🇨🇳 Shanghai, China